Percutaneous nephrolithotomy is considered the gold standard for the removal of large renal stones. Until recently, however, the procedure's efficacy had not been verified by a clinical study as large as a gold-standard procedure would seem to require.
A new study indicates that existing evidence is insufficient to show that most of the tort reforms sought-with the exception of caps on noneconomic damages-would be effective in reducing malpractice claims frequency and costs and defensive medicine, or improving the supply of health care services and quality of care.
Conflicting data on fascial defect size and port fixity render any perception of surgical advantage per port type as theoretical. Thus, regarding this aspect, the decision to use bladed or non-bladed trocars is likely best left to surgeon preference.
The introduction of the computer into the doctor-patient interaction has both benefits and risks.
New urology products and services from American Medical Systems, Caris Life Sciences, UROSKOP Omnia, and Covidien.
Research into the effects of gastric bypass surgery on sperm quality shows no improvement in reproductive capacity among men who undergo the procedure.
This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes U.S. phase I and II localized prostate cancer trials that are currently recruiting participants. This list is current as of April 28, 2010.
Targets for improving the state of management of advanced prostate cancer include the development of new diagnostic modalities with better performance in detecting recurrent disease, additional monotherapy or combination treatment options, and strategies for mitigating the risks of androgen deprivation therapy.
Studies on minimally invasive surgery will again have a prominent place among research being presented on localized prostate cancer at the AUA annual meeting.
Don't give up on instillation for interstitial cystitis when lidocaine doesn't help. Bupivacaine can come to the rescue.
The mechanism of action is somewhat unclear for newer procedures to correct male stress urinary incontinence such as slings, but a new cadaveric model appears to offer valuable insight.
A lower lithotomy position is an acceptable standard approach when performed with adjustable stirrups and pneumatic compression stockings.
A post hoc analysis of two phase III antimuscarinic trials shows that multiple medication use is a major factor in failure of antimuscarinics.
Newer treatments for male sexual dysfunction highlighted at the 2010 AUA annual meeting are allowing urologists to improve patients' quality of life and satisfaction with treatment.
The artificial urinary sphincter appears to be efficacious for the treatment of male stress urinary incontinence, even in complex patients with histories of radiation therapy or urethral surgery.
Pediatric urology is moving fast, bringing developments that will also change not just adult urology, but the practice of medicine as well.
Over the past 2 decades, the field of urology has made dramatic progress in understanding the etiology and pathophysiology of BPH/lower urinary tract symptoms.
Urology drugs and devices that are in the pipeline from Rexahn Pharmaceuticals, Inc., CytRx Corp., Urigen Pharmaceuticals, Inc., Seattle Genetics, Inc., Agensys, Inc., and Millennium: The Takeda Oncology Co.
In diagnosing and treating infection and inflammation, urologists increasingly are using approaches tailored to specific pathogens, patients, and clinical situations.
This year's AUA annual meeting will bring an important first for interstitial cystitis: AUA will be issuing guidelines for diagnosis and treatment.
The advent of robot-assisted surgery is allowing more urologists to perform complex procedures-partial nephrectomies, in particular-which in turn contributes to better patient outcomes.
The number of urodynamic studies conducted by urologists applying for board certification or recertification more than doubled in less than a decade, with most of the procedures being performed in men with symptoms of urinary obstruction and in women with urinary incontinence.
Teva Pharmaceutical Industries Ltd. and Mylan Inc. have separately announced that they received FDA approval for generic versions of tamsulosin hydrochloride capsules, 0.4 mg, for the treatment of signs and symptoms of BPH.
Pinnacle Business Solutions Inc. Medicare Services has announced the retirement of least costly alternative (LCA) local coverage determinations (LCDs) for certain prostate cancer drugs, a move AUA called a "welcome development."
The risk of prostate cancer increases with the number of directly related family members who are affected by the disease, researchers at the German Cancer Research Center in Heidelberg reported.
Exposure to secondhand smoke, coupled with genetic traits, increases the risk of bladder cancer for nonsmokers, reported researchers from the University of Minnesota Masonic Cancer Center, Minneapolis.
A blood test for certain forms of PSA and measurement of DNA content in biopsy tissue accurately predict which men with potentially non-lethal prostate cancers may eventually need treatment, say urologists from Johns Hopkins University, Baltimore.
Gonadotropin-releasing hormone (GnRH) agonists have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several FDA studies.